Mesuximide
Clinical data
Trade namesCelontin
AHFS/Drugs.comConsumer Drug Information
MedlinePlusa682028
Routes of
administration		By mouth (capsules)
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic (demethylation and glucuronidation)
MetabolitesN-desmethylmethosuximide
Elimination half-life1.4–2.6 hours (mesuximide)
28–38 hours (active metabolite)
ExcretionUrine
Identifiers
  • (RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.934 Edit this at Wikidata
Chemical and physical data
FormulaC12H13NO2
Molar mass203.241 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C2N(C(=O)CC2(c1ccccc1)C)C
  • InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3 checkY
  • Key:AJXPJJZHWIXJCJ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]

Medical use

is indicated for the control of absence seizures that are refractory to other drugs.[2]

References

  1. ^ Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.
  2. ^ a b Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
  3. ^ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ (November 1979). "Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy". Neurology. 29 (11): 1509–13. doi:10.1212/wnl.29.11.1509. PMID 116142. S2CID 43643797.
Categories